Healthcare · 13.3

Biotechnology

Quantified news impact based on deduplicated, quality-reviewed events in a single 7-day window.

Average net impact+8weighted per event

Average gross impact14absolute weighted average

Events14same period

Confidence77%model average

Raw intensity62before weighting

Previous period+24net impact

Gross change-43%

Diffusion speed2.0 / day

Concentration9%

Direction disagreement44%

Source independence100%9 sources

IMPACT TREND

7-day effective impact

Positive 11 · Negative 2 · Mixed 1

+260-26

28 Jul, 001 event

28 Jul, 144 events

29 Jul, 040 events

+13

29 Jul, 185 events

+15

30 Jul, 082 events

30 Jul, 220 events

-13

31 Jul, 122 events

1 Aug, 020 events

1 Aug, 160 events

2 Aug, 060 events

2 Aug, 200 events

3 Aug, 100 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term39%74 cumulative effective impact

Medium term52%100 cumulative effective impact

Long term10%19 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 1 of 2 · 14 events

Macro2

Macro29 Jul, 19:58positive

Shenzhen Aims for Strategic Emerging Industries to Hit 2.3 Trillion Yuan, 45% of GDP by 2030

Shenzhen's municipal authorities have issued a plan to develop new quality productive forces and cultivate strategic emerging industries and future industries. By 2030, the city aims for the value-added of strategic emerging industries to reach RMB 2.3 trillion, accounting for 45% of its gross domestic product, with advanced manufacturing as the backbone of a modern industrial system.

Effective: +10
Intensity: 70
Confidence: 60%
Horizon: Long term

Macro29 Jul, 18:34positive

Shanghai Guotou Xian Dao Fund: 900 Billion Yuan Mother Funds Invest 565 Billion Yuan

At the 2026 Science and Technology Innovation Industry Integration Development Conference, Wen Zhi, General Manager of Shanghai Guotou Xian Dao Fund, stated that the three major leading industry mother funds total RMB 900 billion, with cumulative investment decisions of RMB 565 billion and disbursements of RMB 340 billion, leveraging over RMB 2.5 trillion in social capital. Direct investments exceed 70% into early-stage and small enterprises, while 55 sub-funds allocate over 80% to such projects. Wen Zhi outlined four practices addressing the challenges of early-stage investing, supported by policies from 2025 and 2026.

Effective: +9
Intensity: 50
Confidence: 75%
Horizon: Long term

Industries3

Industries30 Jul, 20:00positive

China Insurance Association Completes Drug Selection for Commercial Insurance List; NHSA to Expand Innovative

The China Insurance Association, under the National Financial Regulatory Administration, has completed preliminary drug selection for its commercial insurance drug list, which is pending release. The list differs from the NHSA's commercial insurance innovative drug list and is for pure commercial health insurance. In 2026, the NHSA will expand its innovative drug list for the first time, requiring drugs with strong insurance suitability. Submissions for the NHSA list in 2026 are less than half of 2025. The first NHSA list faced challenges in Huiminbao products, including incomplete discount channels. Alzheimer's drugs lecanemab and donanemab entered national medical insurance in 2026 and are in multiple Huiminbao products. The China Insurance Association is also developing a drug guarantee list to standardize commercial insurance drug lists.

Effective: +24
Intensity: 75
Confidence: 85%
Horizon: Short term

Industries29 Jul, 21:00positive

China's Innovative Drug Out-Licensing Hits 81 Deals ~$110 Billion in H1 2026; 38 Class 1 Drugs Approved

In the first half of 2026, China's innovative drug out-licensing reached 81 deals valued at about $110 billion, already 80% of the full-year 2025 total. Meanwhile, 38 Class 1 innovative drugs were approved for market, including 11 with new targets and mechanisms, all domestically developed. Chinese companies accounted for eight of the top ten global pharmaceutical deals, and total deal value represented about 70% of global M&A. The period also saw the first AI-discovered drug enter Phase III trials in China.

Effective: +21
Intensity: 80
Confidence: 85%
Horizon: Medium term

Industries28 Jul, 19:26positive

15 Pharma Firms in 2026 Fortune 500; Eli Lilly Jumps to 224th as Tirzepatide Tops Global Drug Sales

The 2026 Fortune Global 500 lists 15 pharmaceutical companies, unchanged from 2025 but with reshuffled rankings. Eli Lilly posted the largest leap, rising 112 spots to 224th, with revenue surging 44.7% to $65.179 billion and profit soaring 94.9% to $20.64 billion. Its GLP-1 drug tirzepatide generated $36.507 billion in sales, surpassing Novo Nordisk's semaglutide ($36.1 billion) to become the world's best-selling medicine. Novo Nordisk also gained 35 places, and both companies led profit margins among pharma peers.

Effective: +12
Intensity: 70
Confidence: 85%
Horizon: Medium term

Companies4

Companies30 Jul, 21:56positive

Argenx to Acquire Forte Biosciences for $2.2 Billion in Cash, a 40.5% Premium, Gaining Anti-CD122 Asset FB102

Argenx announced on July 27, 2026, an all-cash acquisition of Forte Biosciences for approximately $2.2 billion, or $77 per share, a 40.5% premium over the prior close. The deal, Argenx's first since its Nasdaq listing, targets FB102, an anti-CD122 antibody modulating IL-12/IL-15 signaling. Phase 1b data for FB102 showed statistically significant benefits in celiac disease and vitiligo, with no serious adverse events.

Effective: +23
Intensity: 75
Confidence: 83%
Horizon: Medium term

Companies28 Jul, 19:04positive

Henlius Serplulimab First to Show Positive Post-Surgery Chemo-Free Result in Gastric Cancer at ASCO

At the 2026 ASCO annual meeting, Peking University Cancer Hospital's Professor Shen Lin presented the ASTRUM-006 phase III study, showing that Henlius' serplulimab achieved the first global positive result for a post-surgery chemotherapy-free regimen in perioperative gastric cancer. The trial involved 57 centers and 588 patients, with a design of three cycles of preoperative chemo-immunotherapy followed by up to 17 cycles of immunotherapy alone. The study met its primary endpoint of event-free survival at the interim analysis in October 2025. Nearly half of gastric cancer patients worldwide are in China, and the Western triple chemotherapy regimen is applicable to less than 10% of East Asian populations. Over the past 30 years, the five-year survival rate for gastric cancer has improved from about 20% to 40-50%.

Effective: +17
Intensity: 85
Confidence: 80%
Horizon: Medium term

Companies29 Jul, 18:24positive

Hengrui's Shudi Insulin Injection Approved as China's First Homegrown Long-Acting Insulin Analogue

Hengrui Medicine announced on July 29 that its independently developed Class 1 biologic Shudi Insulin Injection has been approved by the National Medical Products Administration (NMPA) for market launch. The product is China's first domestically developed long-acting insulin analogue.

Effective: +16
Intensity: 70
Confidence: 80%
Horizon: Medium term

Companies31 Jul, 20:23negative

Alnylam Q2 2026 Product Net Revenue $1.172 Billion, Shares Slump 28% on Guidance Cut

Alnylam reported Q2 2026 product net revenue of $1.172 billion, up 74% year-on-year. Amvuttra sales exceeded $1 billion for the first time, reaching $1.012 billion, up 106%. However, the company trimmed its full-year TTR pipeline sales guidance to $4.2-4.5 billion from $4.4-4.7 billion, sending shares down 28% to a market cap below $30 billion. The company highlighted slowing growth in second-line Amvuttra use in the US, with 80% of new starts being first-line.

Effective: -14
Intensity: 45
Confidence: 75%
Horizon: Short term